[{"orgOrder":0,"company":"Vega Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"VGA039","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Vega Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Vega Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vega Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vega Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"VGA039","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Vega Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Vega Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vega Therapeutics \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Vega Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Peptide-Based Therapeutics Summit
                          Not Confirmed
                          Peptide-Based Therapeutics Summit
                          Not Confirmed

                          Details : VGA039 is a first-in-class antibody therapy that modulates Protein S, a key co-factor involved in thrombin generation during both initiation and propagation of coagulation, it had demonstrated efficacy in numerous congenital bleeding disorders, including...

                          Product Name : VGA039

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          June 04, 2023

                          Lead Product(s) : VGA039

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Peptide-Based Therapeutics Summit
                          Not Confirmed
                          Peptide-Based Therapeutics Summit
                          Not Confirmed

                          Details : VGA039 is a first-in-class antibody therapy that modulates Protein S, a key co-factor involved in thrombin generation during both initiation and propagation of coagulation, it had demonstrated efficacy in numerous congenital bleeding disorders, including...

                          Product Name : VGA039

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          May 23, 2023

                          Lead Product(s) : VGA039

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank